A detailed history of State Street Corp transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 367,468 shares of AVTE stock, worth $955,416. This represents 0.0% of its overall portfolio holdings.

Number of Shares
367,468
Previous 341,190 7.7%
Holding current value
$955,416
Previous $566,000 35.69%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.61 - $2.09 $42,307 - $54,921
26,278 Added 7.7%
367,468 $768,000
Q2 2024

Aug 14, 2024

BUY
$1.41 - $30.75 $156,797 - $3.42 Million
111,204 Added 48.35%
341,190 $566,000
Q1 2024

May 15, 2024

BUY
$17.68 - $29.57 $282,155 - $471,907
15,959 Added 7.46%
229,986 $6.8 Million
Q4 2023

Feb 14, 2024

BUY
$9.58 - $24.25 $311,570 - $788,682
32,523 Added 17.92%
214,027 $4.84 Million
Q3 2023

Nov 14, 2023

SELL
$12.9 - $18.88 $95,073 - $139,145
-7,370 Reduced 3.9%
181,504 $2.46 Million
Q2 2023

Aug 14, 2023

BUY
$15.63 - $22.01 $66,912 - $94,224
4,281 Added 2.32%
188,874 $3.24 Million
Q1 2023

May 15, 2023

SELL
$19.17 - $27.7 $145,519 - $210,270
-7,591 Reduced 3.95%
184,593 $3.72 Million
Q4 2022

Feb 14, 2023

BUY
$15.92 - $30.52 $302,575 - $580,063
19,006 Added 10.97%
192,184 $5.63 Million
Q3 2022

Nov 15, 2022

SELL
$14.77 - $25.79 $79,403 - $138,647
-5,376 Reduced 3.01%
173,178 $2.87 Million
Q2 2022

Aug 15, 2022

BUY
$10.8 - $16.91 $113,583 - $177,842
10,517 Added 6.26%
178,554 $2.79 Million
Q1 2022

May 16, 2022

BUY
$8.25 - $18.33 $113,957 - $253,192
13,813 Added 8.96%
168,037 $3.08 Million
Q4 2021

Feb 14, 2022

BUY
$9.14 - $21.54 $259,402 - $611,326
28,381 Added 22.55%
154,224 $1.82 Million
Q3 2021

Nov 15, 2021

BUY
$11.76 - $22.49 $1.48 Million - $2.83 Million
125,843 New
125,843 $2.64 Million

Others Institutions Holding AVTE

About Aerovate Therapeutics, Inc.


  • Ticker AVTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,448,100
  • Market Cap $63.6M
  • Description
  • Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...
More about AVTE
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.